The phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) is a member of the neutral endopeptidase family, which is expressed predominantly on the plasma membranes of mature osteoblasts and osteocytes. Although it is known that the loss of PHEX function results in X-linked hypophosphatemic rickets, characterized by abnormal bone matrix mineralization and renal phosphate wasting, little is known about how PHEX is regulated. We therefore sought to determine whether the murine PHEX gene is regulated by glucocorticoids (GCs), which are known to influence phosphate homeostasis and bone metabolism. Northern blot analysis revealed increased PHEX mRNA expression in GCtreated suckling mice (1.5-fold) and in rat osteogenic sarcoma (UMR-106) cells (2.5-fold). An increase was also seen in PHEX promoter activity in transiently transfected UMR-106 cells with GC treatment. Analysis of nested promoter deletions revealed that an atypical GC response element was located between Ϫ337 and Ϫ315 bp. Mutational analysis and electrophoretic mobility shift assays further identified Ϫ326 to Ϫ321 bp as a site involved in GC regulation. Supershift analyses and electrophoretic mobility shift assay competition studies indicated that the core binding factor ␣1-subunit transcription factor is able to bind to this region and may therefore play a role in the GC response of the murine PHEX gene.
THE PHOSPHATE-REGULATING gene with homologies to endopeptidases on the X chromosome (PHEX) is a neutral endopeptidase found predominately on the plasma membrane of osteoblasts and osteocytes (1, 8, 16, 20) . Loss of function mutations in the PHEX gene result in X-linked hypophosphatemic rickets (XLH) in humans and, in the animal model of XLH, the Hyp mouse (28) . Manifestations of XLH can vary widely and include vitamin D-resistant rickets, which results in growth retardation, lower body skeletal abnormalities, bone and joint pain, and decreased range of motion (28) . Biochemical characteristics include high serum alkaline phosphatase levels (28) and hypophosphatemia resulting from decreased phosphate reabsorption in the renal proximal tubules (5, 22, 23, 34) . Although the precise physiological function of PHEX is unclear, studies on the Hyp mouse have implicated PHEX in phosphate homeostasis and bone mineralization.
The role of PHEX in phosphate homeostasis has been characterized by means of the Hyp mouse model. The renal phosphate leak seen in the Hyp mouse and in XLH is a result of decreased expression of the sodiumdependent phosphate cotransporter (NaPi-IIa) in the proximal tubules (5, 21, 34) . Additional experiments with the murine model of XLH revealed that the phosphate wasting is the result of a humoral factor, rather than a primary renal defect (15, 24) , and that this circulating factor must be modified by PHEX.
Conversely, the role of PHEX in bone mineralization is not as clear. Clinically, skeletal features of XLH in humans and in Hyp mice include shortened stature, osteomalacia in trabecular and cortical bone, recurrent dental abscesses, and late dentition (28) . The osteomalacia seen is a result of slowed bone remodeling, with a significant delay in osteoid mineralization and reduced resorption (28) . This defective mineralization seen in XLH has also been seen in vitro in cultured, immortalized osteoblasts (38) and in primary cultures of bone marrow cells (20) . Recent studies by Miao et al. (20) on Hyp and normal mice demonstrate that the observed osteomalacia is associated with altered expression of several bone matrix proteins. This altered expression occurred both transcriptionally, with Hyp mice having decreased levels of bone sialoprotein and vitronectin mRNA, and posttranscriptionally, with biglycan and fibrillin immunoreactive protein levels being elevated in Hyp mice while mRNA levels remained unchanged (20) .
Although the physiological results of inactivating mutations in PHEX are known and it is clear that PHEX is involved in regulating bone mineralization and phosphate homeostasis, little is known about how the PHEX gene and protein are regulated. Ecarot et al. (8) have shown that vitamin D 3 is capable of downregulating both PHEX mRNA and protein in cultured primary osteoblasts and in the osteoblast-like cell line MC3T3-E1. However, the effect of vitamin D 3 on PHEX expression in vivo has yet to be determined. More recently, PHEX mRNA was shown to be significantly increased in bones of hypophysectomized rats treated with insulin-like growth factor I (40) . Furthermore, the endopeptidase activity of purified PHEX protein has been shown to be inhibited by inorganic phosphate, inorganic pyrophosphate, and osteocalcin, with the effects of the latter being reversible by Ca 2ϩ (3). We recently cloned and characterized the murine PHEX gene promoter and now have the ability to use this as a tool to investigate transcriptional regulation of the PHEX gene (12) . Computer analysis of the promoter region predicted several putative glucocorticoid (GC) response elements (12) . GCs are known to regulate renal sodium-dependent phosphate reabsorption and to exert both positive and negative effects on bone growth and metabolism. In the present investigation, we sought to determine the following: 1) whether PHEX is regulated by GCs in vivo and in an in vitro cell culture model (UMR-106 cells), 2) whether this regulation is at the level of gene transcription, and 3) whether the cloned murine promoter contains cis-acting elements that mediate this response to GC.
MATERIALS AND METHODS
Experimental animals. Male C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were used in groups of five. Twelveday-old suckling mice were subcutaneously injected with methylprednisolone (MP; Solu-Medrol, Upjohn, Kalamazoo, MI) at a dose of 30 g/g body wt or equal volumes of saline once every 12 h for a total of four injections. Animals were supplied with food and water ad libitum. The animals were killed 3 h after the last injection (at 14 days of age) by CO 2 narcosis followed by cervical dislocation. Calvaria were removed, flash frozen in liquid nitrogen, and stored at Ϫ70°C. All animal procedures were approved in advance by the University of Arizona Institutional Animal Care and Use Committee.
Chemicals and reagents. Lipofectamine, 10ϫ Tris-boric acid-EDTA (TBE), 20ϫ SSC, 100 mM sodium pyruvate, and T 4 DNA ligase were purchased from GIBCO BRL (Bethesda, MD). High-glucose DMEM and fetal bovine serum were from Irvine Scientific (Santa Ana, CA). Taq polymerase, restriction enzymes, and dual luciferase assay kit were from Promega (Madison, WI). DNA oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA). All other reagents, unless otherwise indicated, were purchased from Fisher Scientific (Pittsburgh, PA) or Sigma (St. Louis, MO).
Northern blot analyses. Total RNA was prepared from mouse calvaria or UMR-106 cells with TRIzol Reagent (GIBCO) according to the manufacturer's protocol. Ten micrograms of total RNA were fractionated on a 1% formaldehyde gel and downward transferred to a Zeta-Probe GT nylon membrane (Bio-Rad, Hercules, CA). An antisense PHEX DNA probe was generated by using the PCR EZ strip kit (Ambion, Austin, TX). The probe was synthesized by using PHEX reverse primer 5Ј-TGTCATGTTCAGCTCGAGAG-3Ј, with a PHEX cDNA template from ϩ924 to ϩ1,541 bp [numbered with respect to the identified transcriptional start site (12) Reporter gene constructs. Nested promoter deletions, with the same 3Ј ends, were generated between Ϫ542 and Ϫ133 bp of the PHEX promoter (12) by using the Exo-Size Deletion Kit (New England Biolabs, Beverly, MA). All deletion constructs were confirmed by sequencing. Site-directed scanning mutations were introduced five bases at a time between Ϫ336 and Ϫ317 bp by two-step PCR, as previously described (13) . The resulting mutant constructs were cloned into pGL3-basic (Promega), as previously described (12) . The primers used to construct the mutant promoter constructs were forward Ϫ542 primer, 5Ј-ACTACTGGTACCATTAAGCTCACAC-3Ј; reverse ϩ104 primer, 5Ј-AGCCAATCTAGATGTCTGAACT-GTC-3Ј; mutant 1 forward and reverse, 5Ј-ATCCTCAGGAC-TAGTCTGAAATAAC-3Ј and 5Ј-GTTATTTCAGACTAGTC-CTGAGGAT-3Ј, respectively; mutant 2 forward and reverse, 5Ј-CAGGAAGCTGAGTCCATAACCACTT-3Ј and 5Ј-AAGT-GGTTATGGACTCAGCTTCTTG-3Ј, respectively; mutant 3 forward and reverse, 5Ј-AGCTGCTGAACGCCACACTTTA-GGG-3Ј and 5Ј-CCCTAAAGTGTGGCGTTCAGCAGCT-3Ј, respectively; and mutant 4 forward and reverse, 5Ј-CTGA-AATAACACAGGTAGGGAAACA-3Ј and 5Ј-TGTTTCCCTA-CCTGTGTTATTTCAG-3Ј, respectively. Bold type indicates mutated bases, which were mutated A3 C and G3 T.
Cell culture and transient transfection. Rat osteogenic sarcoma cells (UMR-106) were obtained from the American Type Culture Collection (CRL-1661) and were cultured according to its guidelines. The cells (passages 7-13) were seeded on 24-well plates and cotransfected, by means of liposome-mediated transfection, at 70-80% confluency with 0.5 g of reporter vector DNA and 0.015 g of pRL-TK vector (encoding Renilla luciferase, used as an internal standard; Promega) in serum-free media. Twelve hours after transfection, cells were allowed to recover for 24 h in medium with 10% fetal calf serum followed by 12 h in serum-free medium. Cells were then treated with 10 Ϫ7 M dexamethasone (DEX; Sigma), 10 M mifepristone (RU-486, an antagonist of the GC receptor; Sigma) (36), DEXϩRU-486, or equal amounts of vehicle (ethanol) in medium with charcoal-stripped serum. Twenty-four hours after treatment, cells were harvested, and dual luciferase assays were performed with equal amounts of cellular lysate. To assess the effect of DEX on endogenous PHEX expression in UMR-106 cells, untransfected cells were cultured in 100-mm plates and treated as described above. These experiments were repeated at least three times with separate cell populations on different days. In each experiment, two (for 100-mm plates) or three dishes (for 24-well plates) were considered as n ϭ 1, and the results from these dishes were averaged. Additionally, firefly luciferase activity was normalized for Renilla luciferase activity in each cell extract.
Electrophoretic mobility shift assays. Nuclear protein for electrophoretic mobility shift assays (EMSAs) was prepared from UMR-106 cells as previously described (33) . Doublestranded synthetic olignucleotides were end labeled with [␥- , and H2O to 20 l. For competition studies, 100ϫ of cold probe was added to the reaction. Reactions were incubated at room temperature for 15-20 min. Five microliters of DNA loading buffer [60% 0.25ϫ TBE, 40% glycerol, 0.2% bromphenol blue (wt/vol)] were added, and the reaction was loaded on a 6% DNA retardation gel (Invitrogen, Carlsbad, CA) and electrophoresed at 250 V in 0.5ϫ TBE. Gels were dried and then exposed to X-ray film (Pierce) at Ϫ70°C. For supershift experiments, 2 g of anti-core binding factor (Cbf)␣1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was added to the reaction and incubated at room temperature for 45 min before electrophoresis. Oligos used for EMSAs were PHEX Ϫ332 to Ϫ306 bp, 5Ј-AGCTGCTGAAATAACCACTTTAGGGAA-3Ј; mutant 3, 5Ј-AGCTGCTGAACGCCACACTTTAGGGASA-3Ј; mutant 4, 5Ј-AGCTGCTGAAATAACACAGGTAGGGAA-3Ј; and Cbf␣1, 5Ј-CCCGTATTAACCACAATAAAACTCG-3Ј (Geneka Biotechnology, Montreal, Canada). Bold type indicates mutated bases in mutant 3 and mutant 4 oligos and the core binding sequence in the Cbfal oligo.
Statistical analysis. Statistical significance was determined by Student's t-test or ANOVA followed by Fisher's paired least significant difference, by using the Statview software package version 4.53 (SAS Institute, Cary, NC), and expressed as means Ϯ SE.
RESULTS

GC regulation of PHEX in mice.
To determine the ability of exogenous GCs to regulate PHEX in vivo, 12-day-old mice were treated with pharmacological doses of MP or an equal volume of saline (vehicle). Total RNA was extracted from calvaria and subjected to Northern blot analysis with a PHEX cDNA-specific probe. Results revealed a 1.5-fold increase in PHEX mRNA expression in MP-treated mice compared with controls (Fig. 1A) .
GC regulation of PHEX in UMR-106 cells. Northern blot analysis of rat osteogenic sarcoma UMR-106 cells treated with 10 Ϫ7 M DEX or vehicle revealed a 2.51-fold increase in PHEX mRNA expression in DEXtreated cells compared with ethanol (vehicle)-treated cells (P Ͻ 0.005, n ϭ 3; Figs. 1, B and C) .
Responsiveness of the murine PHEX promoter to GCs. We have previously cloned and shown functionality of the murine PHEX promoter in UMR-106 cells (12) . Preliminary experiments designed to test for GC responsiveness of the previously characterized PHEX promoter fragments (12) showed that the Ϫ542/ϩ104 construct was responsive to DEX whereas the Ϫ133/ ϩ104 construct was not. To better define the region of the promoter responsible for the observed DEX response, a series of nested deletions were constructed between Ϫ542/ϩ104 and Ϫ133/ϩ104. DEX treatment of transiently transfected UMR-106 cells showed no increase in luciferase activity with the Ϫ133/ϩ104 and Ϫ315/ϩ104 constructs; however, the remaining three constructs, Ϫ338/ϩ104, Ϫ354/ϩ104, and Ϫ542/ϩ104 showed a 60-85% increase compared with pGL3-basic (P Ͻ 0.05, n ϭ 7-10; Fig. 2 ). Data are expressed as "fold" increase due to variation in basal promoter activity levels within individual constructs among experiments. However, the fold increases in promoter activity with DEX treatment remained consistent among experiments.
To determine whether this increase in promoter activity by DEX treatment was mediated through the GC receptor, the Ϫ542/ϩ104 construct and pGL3-basic were treated with 10 Ϫ7 M DEX plus 10 M RU-486 or vehicle or 10 M RU-486 only. Addition of 10 M RU-486 to the DEX treatment regime reduced the DEX response from the twofold increase previously seen in the Ϫ542/ϩ104 construct (P Ͻ 0.0001, n ϭ 4-5) to levels that were not different from the RU-486 treated or untreated pGL3-basic levels (Fig. 3) . No difference was seen between treated vehicle and vehicle plus 10 M RU-486 in either of the constructs (data not shown).
Mutational analysis of the PHEX promoter region Ϫ338 to Ϫ315 bp. To determine which base pairs between Ϫ338 and Ϫ315 bp were responsible for the observed DEX response, A3 C and G3 T mutations were introduced five bases at a time between Ϫ336 and Ϫ316 bp by PCR. All the mutations were introduced in the Ϫ542/ϩ104 construct for ease of construction. The four mutant promoter constructs, mutant 1, mutant 2, mutant 3, and mutant 4, (Fig. 4 and Table 1 ) along with the Ϫ542/ϩ104 construct and pGL3-basic were transfected into UMR-106 cells, which were then treated with DEX or vehicle. Analysis of luciferase activity revealed that the DEX response of the mutant 3 construct was significantly reduced (P Ͻ 0.02, n ϭ 4) from the twofold increase in the Ϫ542/ϩ104 construct to levels not significantly different from pGL3-basic (Fig.  4) . The remaining constructs, mutant 1, mutant 2, and mutant 4, showed trends toward reduction in DEXstimulated activity, compared with the wild-type Ϫ542/ϩ104 construct, that were not statistically different from the Ϫ542/ϩ104 construct but were different from pGL3-basic (P Ͻ 0.05, n ϭ 4-5; Fig. 4) .
EMSA analysis of the PHEX promoter region from Ϫ332 to Ϫ306 bp. To assess the ability of transcription factors to bind to the region between Ϫ326 and Ϫ321 bp (encompassing mutant 3), which when mutated showed a loss of DEX response, EMSAs were conducted. Nuclear extracts obtained from UMR-106 cells were incubated with an oligonucleotide probe spanning Ϫ332 to Ϫ306 bp, which resulted in two shifted bands (Fig. 5) . Both of these bands were competed with a 100-fold excess of cold probe (Fig. 5, lane 3) . However, these bands were not competed with an excess of cold mutant 3 probe (Fig. 5, lane 4) . Comparison of Ϫ325 to Ϫ315 bp (the region encompassing mutant 3) of the Table 1 for base pair sequence of wild-type and mutant constructs. LUC, luciferase. B: luciferase activity of the wild-type Ϫ542 promoter construct and mutant promoter constructs. Foldinduction of DEX vs. EtOH and assayed promoter constructs are shown on the y-and x-axes, respectively. * P Ͻ 0.02, significant difference from the wild-type Ϫ542 (n ϭ 4). †P Ͻ 0.05, significant increase in DEX-stimulated luciferase activity compared with pGL3-basic (n ϭ 4-5).
PHEX promoter with known osteoblast-specific transcription factor binding sites showed that mutations 3 and 4 contain a putative osteoblast-specific, cis-acting element (OSE2) (6) to which the transcription factor Cbf␣1 has been shown to bind (7) . Therefore, to determine whether any of the observed shifted bands corresponded to Cbf␣1, we competed the PHEX wild-type probe with an excess of cold probe specific for Cbf␣1. The Cbf␣1 probe was able to compete out both bands seen with the PHEX wild-type probe (Fig. 5, lane 6) . To further confirm the binding of Cbf␣1 to the PHEX probe, an anti-Cbf␣1 antibody was used. The addition of the anti-Cbf␣1 antibody completely removed the highest, shifted band (Fig. 5, lane 7) , indicating that Cbf␣1 was binding to the probe. Additionally, incubation of the Cbf␣1-specific oligonucleotide probe with nuclear extract shifted bands of identical molecular weight to those shifted by the PHEX-specific probe, with the upper band being supershifted by the antiCbf␣1 antibody (Fig. 5, lane 12) . Additionally, because it appeared that Cbf␣1 was capable of binding to the OSE2 site spanning mutations 3 and 4, competition with 100ϫ cold mutant 4 probe, which contains the three 3Ј bases of the OSE2 site, was conducted. Results of this competition revealed that mutations made between Ϫ321 and Ϫ316 bp (mutant 4) could only partially compete the PHEX wild-type probe (Fig. 5, lane  5) . Furthermore, the affinity of the nuclear protein for the PHEX probe was seen to be lower than that for the Cbf␣1 probe (Fig. 5 ) when equal amounts of protein were incubated with equal probe activities.
DISCUSSION
We undertook the present study to determine whether GCs, which are known to have important implications in phosphate homeostasis bone and metabolism, are capable of regulating the PHEX gene. We found that PHEX mRNA isolated from calvaria of suckling mice treated with methlyprednisolone was elevated 1.5-fold compared with that of vehicle-treated mice (Fig. 1) . Additionally, PHEX mRNA expression in the rat osteogenic sarcoma cell line UMR-106 treated with DEX was seen by Northern blot analysis to be elevated ϳ2.5-fold (Fig. 1) . The physiological relevance of this observed upregulation of PHEX by GCs is unclear. Studies on the Hyp mouse showed that PHEX is involved in phosphate homeostasis through transcriptional regulation of the renal NaP i -IIa gene. Furthermore, NaP i -IIa has been shown to be downregulated by GCs at a posttranscriptional level in an age-dependent fashion (9) . Because of these differences in the way that gene expression is effected (up-vs. downregulation) and at what level GC regulation occurs (transcriptional vs. posttranscriptional), it seems unlikely that GC-mediated effects on PHEX expression play a role in NaP i -IIa gene expression. However, GC studies in Hyp and normal littermates will ultimately determine whether GC regulation of the PHEX gene, in turn, alters renal phosphate reabsorption by means of changes in NaPi-IIa expression.
GCs have been reported to exert both positive and negative effects on osteoblasts, the predominant site of PHEX expression. It is well characterized that longterm clinical use of GCs results in serious skeletal side effects, most notably osteoporosis. Weinstein et al. (37) and Silvestrini et al. (32) have both indicated a role for osteoblast apoptosis in GC-induced osteoporosis. However, no correlation has yet been made between PHEX expression and osteoporosis. Additionally GCs were administered over a much longer time period in the studies showing GC-induced osteoblast apoptosis than we used in the present study, making precise comparisons difficult.
GCs have also been shown to exert positive effects on cells of the osteoblast lineage. The addition of GCs to cultured osteoblasts has been shown to promote differ- DNA sequence of the wild-type PHEX promoter between Ϫ336 and Ϫ317 bp. The bases mutated in each mutant construct are indicated in bold. Luciferase activity for each construct in terms of fold-induction Ϯ SE, DEX vs. EtOH, and n value are given for each construct. The putative OSE2 site sequence is indicated by an open box in the wild-type construct. *, Significant difference from the wild-type construct (P ϭ 0.017). entiation (25, 31) , along with increasing the size and amount of bone nodule formation (2, 11, 19, 31) . This increase in nodule formation has further been shown to be greater in less mature than in more mature osteoblastic cells, with the former requiring GCs to differentiate (35) . Therefore, it is likely that the increase in endogenous PHEX mRNA expression seen in UMR-106 cells and the activity of the longer promoter constructs is the result of GC-induced maturation of the relatively immature UMR-106 cells. This is consistent with the observations that PHEX expression increases as osteoblasts differentiate (8) and that DEX increases nodule formation in UMR-106 cells (11) . The observation that there are two populations of osteoblastic cells that respond differently to GCs would also explain the difference in GC response seen between the in vitro and in vivo studies. UMR-106 cells, which are a homogenous population of relatively immature osteoblasts, show a 2.5-fold increase in PHEX expression with GC treatment, whereas a more modest 1.5-fold increase in expression is seen in mice calvaria, which contain a more heterogeneous population of osteoblasts at different stages of maturation.
Analysis of PHEX promoter constructs transfected into UMR-106 cells showed that treatment with 10
Ϫ7
M DEX significantly increased (P Յ 0.006) promoterdriven luciferase activity from the Ϫ542/ϩ104 construct compared with the promoterless luciferase vector pGL3-basic. This twofold increase in promoter activity is consistent with the observed DEX increase in endogenous PHEX expression in UMR-106 cells. To define the region of the promoter responsible for upregulation by GCs, a series of nested deletions of the Ϫ542/ϩ104 promoter construct were produced and assayed for GC responsiveness. Results revealed that the Ϫ337/ϩ104 construct responded to DEX, whereas the Ϫ315/ϩ104 construct, which is only 23 bases shorter, was unresponsive. This indicated that a cis-element responsible for GC upregulation was likely between Ϫ337 and Ϫ315 bp of the PHEX gene promoter. Analysis of the DNA sequence from Ϫ337 to Ϫ315 bp revealed the lack of a classical GC response element(s); however, the ability of RU-486 to abolish the GC response indicated an effect mediated by the GC receptor.
To further define the bases responsible for GC regulation, site-directed mutations were introduced into the Ϫ542/ϩ104 promoter construct between Ϫ336 and Ϫ316 bp ( Table 1) . Analysis of these promoter mutants revealed that only mutations introduced in mutant 3, between Ϫ326 and Ϫ321 bp, resulted in a significant (P Ͻ 0.05, n ϭ 4) reduction in DEX-induced luciferase activity compared with the wild-type Ϫ542/ϩ104 construct. When the bases mutated in the mutant 3 construct along with three bases flanking each side of the mutation were scanned with Matinspector (Genomatrix, Munich, Germany; http://genomatix.gsf.de/) for putative transcription factor binding sites, no potential cis-acting elements were identified. As PHEX is predominantly expressed in mature osteoblasts and osteocytes (8, 10, 20, 29) , these bases were further examined manually for potential osteoblast-specific transcription factor binding sites. A single OSE2 site (6) , to which the transcription factor Cbf␣1 has been shown to bind (7), was found to span one-half of mutant 3 and onehalf of mutant 4. Cbf␣1 is a member of the runt gene family with homology to the DNA-binding domain of the Drosophila runt gene (26) and has been shown to be necessary for osteoblast differentiation (7, 14, 27) . Furthermore, Cbf␣1 is capable of regulating the osteoblast genes osteocalcin, osteopontin, and ␣1(I) collagen (7, 39) and is itself regulated by 1,25(OH) 2 vitamin D 3 (7), GCs (4), and parathyroid hormone (30) . Interestingly, these three hormones are also important in bone metabolism and phosphate homeostasis.
To determine whether this putative Cbf␣1-binding site was capable of binding Cbf␣1, an EMSA was conducted utilizing a probe from Ϫ332 to Ϫ306 bp, encompassing the bases mutated in the mutant 3 construct. The EMSA revealed that the PHEX Ϫ332 to Ϫ306 bp probe shifted two bands when incubated with UMR-106 nuclear protein. Both of these bands were competed with 100ϫ cold PHEX and Cbf␣1-specific probes but neither were competed with the PHEX mutant 3 probe. Furthermore, the Cbf␣1-specific probe shifted bands identical to those of the PHEX Ϫ332 to Ϫ306 bp probe. Additionally, the affinity of the nuclear proteins for the Cbf␣1-specific probe was much greater than for the PHEX probe. To determine whether one or more of the shifted bands contained the Cbf␣1 protein, supershift analyses were conducted with an anti-Cbf␣1 antibody. With addition of anti-Cbf␣1 antibody, the upper shifted band seen with the PHEX probe was abolished, whereas the same band with the Cbf␣1-specific probe was shifted to a higher molecular weight. The inability of the anti-Cbf␣1 antibody to supershift the upper PHEX probe band is likely the result of disruption of the much weaker interaction of Cbf␣1 with the PHEX probe compared with the Cbf␣1-specific probe.
Taken together, the EMSA data and the results with promoter mutant 3 suggest that Cbf␣1 may play a role in the GC response of the PHEX gene. This would appear to be in contrast with the results of Liu S et al. (17) , who reported that overexpression of Cbf␣1 had no effect on luciferase activity driven by the murine PHEX promoter. However, these authors only evaluated the ability of Cbf␣1 to stimulate promoter expression and did not appear to consider the possibility of repression of PHEX expression by Cbf␣1. The ability of Cbf␣1 to repress PHEX expression would be consistent with the recent observations by Liu et al. (18) , which showed that late-stage osteoblast maturation was blocked in transgenic mice overexpressing Cbf␣1, along with those of Ecarot et al. (8) and Miao et al. (20) , who showed PHEX expression is highest in fully differentiated osteoblasts and osteocytes. In light of these findings, it is possible that Cbf␣1 may serve to repress PHEX expression in nonmature osteoblasts. Therefore, attempts to alter PHEX promoter expression, in an osteoblastic cell line that endogenously expresses Cbf␣1, by overexpressing Cbf␣1 would likely result in no change in promoter activity. Additionally, studies by Chang et al. (4) showed that GCs decreased immu-noreactive Cbf␣1 protein in primary rat osteoblasts. Therefore, our findings along with those of Liu et al. (18) and Chang et al. (4) suggest that the GC-induced increase in PHEX expression in suckling mice and UMR-106 cells, along with increased PHEX promoter activity in GC-treated UMR-106 cells, may result from removal of Cbf␣1 from the promoter, which may act to repress PHEX expression.
In conclusion, we have demonstrated that the rodent PHEX gene is regulated by GCs through the GC receptor and that this regulation is, at least in part, mediated at the transcriptional level. Furthermore, we have identified position Ϫ326 to Ϫ321 bp in the murine PHEX promoter as a site involved in this regulation. Additionally EMSA analysis of the GC responsive region indicates that the osteoblast transcription factor Cbf␣1 is likely involved. Future studies will define the precise role Cbf␣1 plays in the expression of the PHEX gene and its regulation by GCs.
